Does Medicare Cover Stem Cell Therapy? The 2026 Coverage-Gate Framework

Introduction: Why “Does Medicare Cover Stem Cell Therapy” Isn’t a Yes/No Question

For Medicare beneficiaries with knee, hip, or shoulder osteoarthritis, the question “does Medicare cover stem cell therapy” is often the main financial decision point. The answer determines whether a patient goes on to research providers, sets aside personal funds, or turns to other treatments.

Most online answers stop at a flat “no,” followed by a cost-sharing table for blood cancer transplants. That leaves orthopedic patients without an explanation of why coverage is denied or what to do next.

This article uses a coverage-gate framework. Medicare coverage depends on a two-part regulatory test: FDA approval, then a determination that a treatment is “reasonable and necessary.” Clinical outcomes data alone does not decide it. The sections below cover:

1. The direct answer about what Medicare covers
2. The regulatory mechanics behind the “no”
3. The clinical evidence and safety concerns that reinforce it
4. The realistic path to future coverage
5. Two legitimate next steps available to beneficiaries today

The Direct Answer: What Medicare Actually Covers

Medicare’s stem cell coverage is narrow, binary, and tied to specific conditions. It is not a general “stem cell therapy” benefit.

The Two FDA-Approved Indications Medicare Covers

Medicare covers two types of stem cell procedures:

• Allogeneic hematopoietic stem cell transplantation (HSCT), which uses cells from a donor
• Autologous stem cell transplantation (AuSCT), which uses the patient’s own cells

Both are covered only for blood cancers and blood disorders, including leukemia, lymphoma, multiple myeloma, and aplastic anemia, as outlined by Medicare’s coverage policy for stem cell transplants.

These are FDA-regulated, physician-administered hospital procedures. They have very little in common with orthopedic mesenchymal stem cell (MSC) or bone marrow aspirate concentrate (BMAC) injections offered at outpatient clinics. Standard Part A and Part B cost-sharing applies to covered transplants. Because those figures change each year, beneficiaries should check Medicare.gov or their plan documents for current amounts.

NCD 110.23: The Rule That Governs Coverage

Coverage for these transplants is defined by National Coverage Determination (NCD) 110.23, the CMS policy document that states when HSCT is considered “reasonable and necessary.”

NCDs apply to specific conditions and specific procedures; they do not extend to related uses on their own. Before any new use, including orthopedic applications, could be covered, CMS would need to issue a new NCD or formally expand an existing one.

The 2024 MDS Expansion: Proof CMS Does Update Coverage

In March 2024, CMS expanded NCD 110.23 to cover allogeneic HSCT for patients with myelodysplastic syndromes (MDS) who meet specific prognostic risk-score thresholds:

• IPSS score of 1.5 or higher
• IPSS-R score of 4.5 or higher
• IPSS-M score of 0.5 or higher

This shows that CMS coverage can change through a formal National Coverage Analysis as evidence builds. CMS had previously concluded, in 2010, that the evidence did not show allogeneic HSCT improved outcomes for MDS, and it revisited that conclusion once the data matured.

The MDS expansion also shows what was required: it happened only after FDA-regulated products and a well-developed evidence base were in place. Orthopedic stem cell therapy does not yet have either.

The Real Question: Why Doesn’t Medicare Cover Orthopedic Stem Cell Therapy?

Medicare’s “no” for orthopedic stem cell therapy is not a ruling on patient outcomes. These therapies stop at the first regulatory gate and never reach a review of their results.

CMS’s Two-Part Test: FDA Approval + “Reasonable and Necessary”

The process runs in order:

1. Gate one: The product or procedure must have FDA approval.
2. Gate two: CMS decides whether the approved product is “reasonable and necessary” for a specific condition.

Orthopedic MSC, BMAC, and adipose-derived stem cell products never get to gate two. Because no approved biologic product exists for these uses, CMS has nothing to evaluate. The barrier is structural and does not mean regulators have dismissed the therapy’s potential.

No FDA-Approved Biologic Product Exists for Orthopedic Use

As of 2026, no allogeneic stem cell, exosome, or micronized birth-tissue product is FDA-approved for sale for any condition in the United States.

Some orthopedic clinics use point-of-care autologous products, meaning cells taken from the patient’s own body and returned during the same visit. These are not “FDA-approved drugs” in the sense that matters for Medicare coverage.

The 351 vs. 361 Distinction: Why Clinics Can Legally Operate Without Medicare Coverage

The FDA regulates cell and tissue products on two tracks:

Track	Regulatory Basis	What It Means
Section 351	Biologics License Application (BLA)	Full drug/biologic approval with clinical trials; the standard CMS requires for coverage
Section 361	21 CFR Part 1271 (minimal manipulation, same-day exception)	Narrower framework for minimally manipulated tissue used in the same procedure

Most point-of-care autologous BMAC and adipose procedures fall under the narrower Section 361 framework. A clinic can perform them legally, but that status is not the same as the full approval CMS needs before it can consider coverage.

This explains a situation that confuses many patients: a clinic can legally offer a procedure while Medicare has no obligation, and no process, to pay for it.

The Clinical Evidence Behind the Coverage Gate

Even without the FDA-approval requirement, the current orthopedic evidence would probably not meet the “reasonable and necessary” standard.

What Major Orthopedic and Rheumatology Societies Say

The major professional societies have taken specific positions:

• American Academy of Orthopaedic Surgeons (AAOS): Its knee osteoarthritis clinical practice guideline makes no formal recommendation because the evidence is insufficient to rate.
• American College of Rheumatology / Arthritis Foundation: Recommends against stem cell injections.
• AAHKS, The Hip Society, and The Knee Society: A joint statement says that “biologic therapies, including stem cell and PRP injections, cannot currently be recommended for the treatment of advanced hip or knee arthritis.”

Many consumer articles summarize this as “insufficient evidence” without naming sources. The specific positions above carry more weight.

The 2024 Meta-Analysis: What the Data Actually Shows

A 2024 systematic review and meta-analysis by Sadeghirad and colleagues pooled 16 randomized controlled trials involving 807 patients. It concluded that intra-articular MSCs “probably provide little to no improvement in pain or physical function” for knee osteoarthritis.

Before CMS would consider a National Coverage Analysis, this body of research would need to grow and point consistently toward benefit.

Why Clinical Outcomes Data Alone Can’t Unlock Coverage

Some clinics report strong real-world results, including high patient satisfaction and low rates of later joint replacement. Under CMS’s framework, those reports cannot take the place of FDA approval.

For this reason, even well-run clinics with good outcomes data are outside Medicare coverage. At this stage the barrier is the approval process, not the quality of a clinic’s results.

The Safety Dimension: Why FDA Enforcement Reinforces the Coverage Gap

The coverage gap is also tied to patient safety and to active enforcement by regulators.

2025–2026 FDA Enforcement Actions Against Unapproved Stem Cell Marketers

Throughout 2026, the FDA’s Center for Biologics Evaluation and Research (CBER) has continued to focus on unapproved stem cell therapies. Its warning letters have targeted companies marketing allogeneic umbilical cord and Wharton’s Jelly-derived products, as well as exosomes.

A prominent example is the August 2026 warning letter to R3 Medical Companies, which cited unlicensed biologics and manufacturing violations.

For patients, the point is that missing Medicare coverage and missing FDA approval reflect the same safety concern. The coverage decision is not an arbitrary insurance restriction.

The Scale of the Unregulated Clinic Industry

The direct-to-consumer stem cell market has grown quickly:

• 2016: Researchers identified 351 businesses operating 570 clinics selling unlicensed stem cell interventions.
• 2021: An estimated 1,480+ businesses were operating 2,754+ clinics, more than four times as many.

With that many providers, checking a clinic’s regulatory compliance matters more than reading its marketing.

Even FDA-Approved Cell Therapies Have Age-Related Caveats

MACI (matrix-induced autologous chondrocyte implantation), approved by the FDA in 2016 for knee cartilage defects, is the one approved cell-based orthopedic product. Its label states that safety and effectiveness have not been established in patients over age 55.

Nearly all Medicare beneficiaries are older than that, so they fall outside the population in which MACI was studied. FDA approval does not always mean a treatment has been proven for every age group.

The Path to Future Coverage: Mapping the Regulatory Pipeline

Patients also want to know what would have to happen for coverage to change, and how long it might take.

Step One: RMAT Designation

The 21st Century Cures Act of 2016 created the Regenerative Medicine Advanced Therapy (RMAT) designation, which speeds development for promising regenerative products that treat serious conditions.

On September 25, 2025, the FDA released updated draft RMAT guidance. It allows sponsors to use real-world evidence, such as patient registries and electronic health records, in place of some traditional confirmatory trials. This could help future orthopedic approvals move faster.

Step Two: BLA Approval

A sponsor must finish Phase 1 through 3 clinical trials and receive BLA approval before CMS can begin considering coverage. A large Phase III trial announced in January 2026 shows the pipeline is moving. One trial, however, will not change coverage in the near term.

Step Three: Coverage with Evidence Development (CED) and the 2024 MDS Precedent

Coverage with Evidence Development lets CMS grant conditional coverage while requiring registry participation or further data collection. The 2024 MDS expansion is the clearest recent example of CMS extending coverage to a new stem cell use once FDA-regulated products and enough evidence existed.

A Realistic Timeline

Industry analysts estimate that orthopedic stem cell approvals relevant to insurance are unlikely before 2028 to 2029, and Medicare coverage would come after that. Patients should be cautious about any marketing that suggests Medicare coverage is imminent.

What Medicare Beneficiaries Can Do Today: Two Legitimate Next Steps

Beneficiaries do not need to go offshore or travel abroad for treatment. Two legitimate options exist in the United States.

Pathway 1: CMS-Qualifying Clinical Trials Under NCD 310.1

NCD 310.1 (Routine Costs in Clinical Trials) allows Medicare to pay for routine care costs, such as office visits, imaging, and standard monitoring, for beneficiaries enrolled in CMS-qualifying clinical trials. Medicare does not pay for the investigational product itself.

To explore this option, patients can:

• Search ClinicalTrials.gov for active trials studying stem cell therapy for their condition
• Ask a physician whether a trial qualifies under CMS rules or involves a CED registry
• Confirm with the trial site which costs Medicare covers and which the sponsor covers

This is the most financially protected way to receive investigational stem cell therapy.

Pathway 2: Transparent Self-Pay Evaluation at FDA-Compliant U.S. Clinics

Patients who choose not to wait for a trial can seek an evaluation at a domestic clinic. A transparent, FDA-compliant evaluation should include:

• Clear disclosure of regulatory status, including that the treatment is not FDA-approved for orthopedic conditions
• Imaging-guided procedures, such as ultrasound or X-ray guidance, for accurate placement
• A personalized assessment that considers age, inflammation, injury type, medications, and goals

A provider that openly states a treatment is not FDA-approved is more trustworthy than one that implies FDA clearance. Patients should also ask for itemized pricing in writing and understand that treatment will be fully self-pay, no matter where the clinic is located.

A Note on State “Right to Try” Laws

Several states have passed laws allowing non-FDA-approved stem cell therapies for orthopedic, wound care, and pain uses. These include Florida (SB 1768, signed in 2025), Montana, Wyoming, Utah, and Nevada.

These laws expand legal access to treatment. They do not require Medicare or private insurers to pay for it. Patients treated under these laws pay the full cost themselves. Marketing sometimes blurs this point, so patients should keep it in mind.

Covered Alternatives Worth Discussing With Your Doctor

A lack of coverage for stem cell therapy does not mean a lack of covered options for joint pain. Treatments that are more established, and often covered by Medicare, include:

• Physical therapy to strengthen muscles around the joint and improve how it moves
• Hyaluronic acid (viscosupplementation) injections for joint lubrication
• Genicular nerve blocks and genicular artery embolization for knee pain
• Joint replacement, when it is medically necessary

Genicular artery embolization is a newer option with encouraging data. Studies report a 99.7% technical success rate and pain reductions of 34 to 39 points on the Visual Analog Scale (VAS).

Patients interested in stem cell therapy should bring it up with their physician as part of a broader discussion of all their treatment options.

Medicare Advantage and Supplemental Plans: Common Misconceptions

• Medicare Advantage plans must cover at least what Original Medicare covers. They cannot independently add orthopedic stem cell therapy as a covered medical benefit.
• Discount and wellness programs are not insurance. Some Medicare Advantage or supplemental programs offer discounts or wellness perks that may sound like coverage but are not actual insurance benefits.
• Get it in writing. Beneficiaries should request a written coverage determination from their plan before assuming any stem cell benefit exists.

Frequently Asked Questions

Does Medicare cover stem cell therapy for knee osteoarthritis?
No. Medicare covers stem cell transplantation only for certain blood cancers and blood disorders under NCD 110.23. Because no FDA-approved stem cell product exists for knee osteoarthritis, the treatment cannot qualify for coverage.

Is stem cell therapy FDA-approved?
Not for orthopedic use. Many clinics perform minimally manipulated, same-day autologous procedures legally under Section 361 (21 CFR Part 1271). That is different from the full Section 351 BLA approval that Medicare coverage requires.

Will Medicare ever cover orthopedic stem cell therapy?
It is possible. A product would first need RMAT designation (optional but faster), then BLA approval, then a CMS coverage decision, possibly through Coverage with Evidence Development. Analysts expect insurance-relevant approvals no earlier than 2028 to 2029.

Can a state Right to Try law make Medicare pay?
No. State Right to Try laws expand legal access to treatment but do not affect Medicare or private insurance coverage.

Conclusion: Making an Informed Decision at the Coverage Gate

Medicare does not cover orthopedic stem cell therapy because its framework requires FDA approval first, and no approved product exists for these uses. This does not mean the field lacks potential. Professional society positions, current meta-analysis findings, and active FDA enforcement in 2025 and 2026 all support caution in the meantime.

Beneficiaries have two legitimate options today: enrolling in a clinical trial with routine-cost coverage under NCD 310.1, or getting a transparent, FDA-compliant self-pay evaluation at a U.S. clinic. Unregulated and offshore providers carry real risks. With an accurate picture of the coverage situation, patients and caregivers can make an informed choice about their next step.

Explore Your Options With a Transparent, FDA-Compliant Provider

Unicorn Bioscience is a U.S.-based regenerative medicine provider offering personalized evaluations for orthopedic conditions. It has locations in Austin, Dallas, El Paso, Fort Worth, Houston, and San Antonio, Texas; Boca Raton, Florida; and Manhattan, New York.

The company states openly that, as of 2026, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions. It offers a domestic alternative to medical tourism, with imaging-guided injections and treatment plans based on each patient’s age, inflammation, injury type, medications, and goals.

Patients who want to know whether a regenerative medicine evaluation fits into their broader treatment plan can schedule a virtual or in-person consultation:

• Phone: (737) 347-0446
• Website: unicornbioscience.com

Any self-pay decision should be made with a clear understanding of the coverage facts described in this article and, ideally, together with the patient’s primary physician.